By: Naureen Rehman, Muzna Hashmi, Sher Muhammad Sethi, Sara Hafeez, Aimun Shabbir, Muhammad Ali, Varisha Madni, Muhammad Zain Mushtaq, Saad Bin Zafar Mehmood, Faheem Shaikh, Farhala Baloch, Rabeea Azmat, Sumera Batool, Ainan Arshad
Keywords: Diabetes; glycemic control; HbA1c; linagliptin; SGLT-2 inhibitors
DOI : 10.36721/PJPS.2025.38.4.REG.13714.1
Abstract: This study compares linagliptin and SGLT-2 inhibitors to optimize diabetes management by evaluating their glycemic and non-glycemic effects. A cross-sectional study was conducted at the Aga Khan University Hospital, Karachi, from May to October 2023. Patients using linagliptin were assigned to group 1, while those on SGLT-2 inhibitors comprised group 2. Frequencies and percentages were used for categorical variables, and mean with standard deviation (SD) for continuous variables. An independent t-test assessed clinical outcomes before and after six months of treatment, with a significance threshold of p<0.05. Of the 278 patients enrolled (mean age: 53 years, SD: 13.4; 55.2% male), 39 were in group 1, and 239 in group 2. SGLT-2 inhibitors showed a greater reduction in HbA1c (-0.66 vs. -0.46, p=0.002) and diastolic blood pressure (mean difference: 2.65 mmHg, p=0.005). Linagliptin significantly reduced BMI (mean difference: 0.65 kg/m², p=0.03), while no significant weight change was observed with SGLT-2 inhibitors. SGLT-2 inhibitors provided superior glycemic control and reduced blood pressure, while linagliptin was more effective in lowering BMI. Further studies are needed to explore linagliptin’s potential benefits.
[View Complete Article]
